Rates and risk factors of monoresistance against isoniazid and multidrug-resistant tuberculosis in Almaty, Kazakhstan

Juliana G E Bartels, Nurlan Takenov, Lyailya Chingissova, Anar S. Rakisheva, Ainur Eleusizova, Venera Bismilda, Lyazzat T. Yeraliyeva, Yanis Ben Amor

BMC Infectious Diseases, 2026

Full text Open access: Gold Metadata (CSL-JSON)
DOI 10.1186/s12879-026-12629-8
Data confidence 70 medium
How this score is calculated

It is built from checkable properties of the record itself: whether the article has a DOI, how many independent sources confirmed its data, whether the required fields are filled in, and how recent the latest confirmation is. Disagreement between sources and a missing identifier lower it. A value of 80 or above means the record was published without further checking; 60 to 79 means it is published at reduced confidence, with a manual check advisable. A record verified by an editor by hand is never pushed below 90 by a recalculation. This scores our data about the article, not the article itself.

Abstract

BACKGROUND: Drug resistant tuberculosis (DR-TB) poses a massive threat to public health, and monoresistance to isoniazid (Hr-TB) is not often diagnosed. This study aims to determine rates of Hr-TB and multidrug resistance (MDR-TB) among TB isolates and assess risk factors for TB diagnosis and drug resistance in Almaty, Kazakhstan to inform public health policy. METHODS: From December 2021 to July 2022, sputum samples were collected from 1214 unique patients over age 18 with presumptive TB who were not currently on TB treatment. All samples were tested with both Mycobacterial Growth Indicator Tube (MGIT) liquid culture and the Becton-Dickinson real-time PCR (BD MAX™ MDR-TB) for detection of M. tuberculosis and drug resistance to isoniazid (INH), rifampicin (RIF), ethambutol (EMB), and pyrazinamide (PZA). Rates of monoresistance and MDR-TB were calculated, and univariate and multivariable logistic regression models were run to determine odds ratios for potential risk factors for TB, Hr-TB, and MDR-TB diagnosis using MGIT results. RESULTS: Any resistance to INH was found in 115 (43.7% [95% CI: 37.9-49.8%]) of 263 TB isolates diagnosed by MGIT, and Hr-TB was diagnosed in 34 MGIT TB isolates (12.9% [95% CI: 9.4-17.5%]). Among 359 BD MAX TB isolates, 51 (14.2% [95% CI: 11.0-18.2%]) were Hr-TB. MDR-TB was diagnosed in 70 MGIT TB isolates (26.6% [95% CI: 21.6-32.3%]) and 65 BD MAX TB isolates (24.7% [95% CI: 14.5-22.4%]). Male patients, those aged 35-44 and 45-54, and patients with self-reported diabetes mellitus had higher odds of TB diagnosis compared to female patients, those aged 65+, and those with no self-reported comorbid conditions, but no significant associations were found between patient characteristics and odds of Hr-TB or MDR-TB diagnosis. CONCLUSION: Rapid and accurate diagnosis of INH monoresistance is critical to understand national burdens of Hr-TB, improve treatment regimens, and prevent increases in MDR-TB in Kazakhstan. Current TB diagnostics that do not detect resistance to INH are inadequate to characterize Hr-TB. Therefore, high-burden MDR-TB countries should consider using diagnostics that detect resistance to both INH and RIF in national TB prevalence and drug resistance surveys. CLINICAL TRIAL: Not applicable.